Cory Mavis Selected Research

Rituximab (Mabthera)

11/2023	Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.
1/2022	Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.
12/2020	Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab.
12/2020	The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance.
12/2018	The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma.
4/2018	Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.
1/2018	Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development.
1/2018	A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma.
2/2017	Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells.
3/2016	Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cory Mavis Research Topics

Disease

16	Lymphoma (Lymphomas) 11/2023 - 06/2011
12	B-Cell Lymphoma (Lymphoma, B Cell) 01/2023 - 12/2010
10	Neoplasms (Cancer) 01/2023 - 06/2014
5	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2023 - 02/2016
4	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2022 - 06/2014
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018 - 12/2010
2	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 05/2015 - 02/2012
1	Residual Neoplasm 01/2022
1	COVID-19 01/2021
1	Type 2 Diabetes Mellitus (MODY) 01/2020
1	Burkitt Lymphoma (Burkitt's Lymphoma) 04/2018
1	T-Cell Lymphoma (Lymphoma, T Cell) 05/2015
1	Multiple Myeloma 09/2013
1	Hematologic Neoplasms (Hematological Malignancy) 12/2010

Drug/Important Bio-Agent (IBA)

18	Rituximab (Mabthera)FDA Link 11/2023 - 06/2011
5	Bortezomib (Velcade)FDA Link 02/2017 - 12/2010
4	Proteasome InhibitorsIBA 12/2018 - 12/2010
3	carfilzomibIBA 11/2023 - 09/2013
3	Proteasome Endopeptidase Complex (Proteasome)IBA 11/2023 - 09/2013
3	ofatumumab FDA Link 01/2022 - 02/2012
3	EnzymesIBA 07/2020 - 06/2014
3	CaspasesIBA 12/2018 - 11/2013
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2023 - 06/2014
2	Apoptosis Regulatory ProteinsIBA 01/2023 - 09/2013
2	Proteins (Proteins, Gene)FDA Link 12/2020 - 12/2010
2	pevonedistatIBA 07/2020 - 03/2016
2	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 07/2020 - 03/2016
2	Histone Deacetylases (Histone Deacetylase)IBA 02/2016 - 05/2015
2	Histone Deacetylase InhibitorsIBA 02/2016 - 05/2015
1	Prednisone (Sone)FDA LinkGeneric 11/2023
1	UbiquitinIBA 11/2023
1	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2023
1	Vincristine (Oncovin)FDA LinkGeneric 11/2023
1	tapotoclaxIBA 01/2023
1	Complement System Proteins (Complement)IBA 01/2022
1	PolymersIBA 12/2020
1	Biocompatible Materials (Biomaterials)IBA 12/2020
1	AntibodiesIBA 12/2020
1	daratumumabIBA 12/2020
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 12/2020
1	Metformin (Glucophage)FDA LinkGeneric 01/2020
1	Glucose (Dextrose)FDA LinkGeneric 01/2018
1	HexokinaseIBA 01/2018
1	Protein Isoforms (Isoforms)IBA 01/2018
1	pegfilgrastim (Neulasta)FDA Link 01/2018
1	Cyclin BIBA 02/2017
1	Vorinostat FDA Link 02/2016
1	entinostat (MS 275)IBA 05/2015
1	NucleotidesIBA 06/2014
1	fludarabineIBA 06/2014
1	temsirolimus FDA Link 06/2014
1	Bendamustine Hydrochloride FDA Link 06/2014
1	Gemcitabine FDA Link 06/2014
1	Cisplatin (Platino)FDA LinkGeneric 06/2014
1	Cytarabine (Cytosar-U)FDA LinkGeneric 06/2014
1	Deoxycytidine KinaseIBA 06/2014
1	NucleosidesIBA 06/2014
1	Cladribine FDA LinkGeneric 06/2014
1	MLN2238IBA 11/2013
1	Therapeutic UsesIBA 06/2011
1	obatoclaxIBA 06/2011

Therapy/Procedure

11	Drug Therapy (Chemotherapy) 11/2023 - 06/2011
8	Therapeutics 01/2023 - 12/2010
1	Immunotherapy 01/2020
1	Investigational Therapies (Experimental Therapy) 06/2014